|Cephalon FDA Approval For Risk Evaluation And Mitigation Strategy. Celsion Announces $18.4 Million In Financing.|
|By Staff and Wire Reports|
|Thursday, 21 July 2011 20:12|
Cephalon, Inc. (NASDAQ:CEPH) announced the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA (fentanyl buccal tablet) [C-II] and ACTIQ (oral transmucosal fentanyl citrate) [C-II].
Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare professionals who prescribe FENTORA and ACTIQ will enroll by completing an education module and knowledge assessment focused on safety information including appropriate patient selection.
Celsion Corporation (NASDAQ:CLSN), announced it has received commitments from investors to purchase an aggregate of $18.4 million of the Company's securities, of which $13.0 million are from institutional investors in a registered direct offering and an additional $5.4 million are from other investors. In the registered direct offering, the Company entered into definitive purchase agreements with investors pursuant to which the Company agreed to sell an aggregate of approximately 3.0 million shares of its common stock and warrants potentially exercisable for up to approximately 914,305 additional shares of its common stock. The securities will be sold in units at a price of $4.2575 per unit, with each unit consisting of one share of common stock.
In the private placement, the Company agreed to sell an aggregate of approximately 1.3 million shares of its common stock and warrants potentially exercisable for up to approximately 512,412 additional shares of its common stock.
The securities will be sold in units at a price of $4.27 per unit, with each unit consisting of one share of common stock. The Company intends to use the net proceeds from the offerings for general corporate purposes, including the funding of the clinical development of its product pipeline of cancer drugs.
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has entered into an agreement with CHA Bio & Diostech Co, Ltd. ("CHA Biotech"), a leading South Korea-based biotechnology company, designed to enhance the efforts of the two companies' international joint venture, Stem Cell & Regenerative Medicine International (SCRMI).
Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named retired four-star General Merrill A. McPeak to its Board of Directors.
Idenix Pharmaceuticals, Inc., (NASDAQ:IDIX) announced today that it will report its financial results for the second quarter of 2011 on Monday, August 8, 2011 after U.S. financial markets close.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B. ISIS-PTP1BRx is designed to increase the body's sensitivity to the natural hormone insulin, resulting in better glucose control for patients with type 2 diabetes.
PAREXEL International Corporation (NASDAQ:PRXL), a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs.
Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the second quarter of 2011 after closing of the NASDAQ Global Market on Thursday, August 4, 2011.
United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will release its second quarter 2011 financial results before market open on Thursday, July 28, 2011.
ViroPharma Incorporated's (Nasdaq:VPHM) second quarter financial results for 2011 are expected to be released on Thursday, July 28, 2011 before the open of the U.S. financial markets.